Foster & Motley Inc. Has $1.30 Million Position in The Cigna Group (NYSE:CI)

Foster & Motley Inc. increased its stake in shares of The Cigna Group (NYSE:CI) by 3.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 4,341 shares of the health services provider’s stock after buying an additional 158 shares during the period. Foster & Motley Inc.’s holdings in The Cigna Group were worth $1,300,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Bogart Wealth LLC lifted its holdings in shares of The Cigna Group by 104.5% during the third quarter. Bogart Wealth LLC now owns 90 shares of the health services provider’s stock worth $26,000 after buying an additional 46 shares in the last quarter. OFI Invest Asset Management bought a new stake in The Cigna Group in the 3rd quarter valued at about $26,000. Fortitude Family Office LLC bought a new position in shares of The Cigna Group during the fourth quarter worth approximately $29,000. VisionPoint Advisory Group LLC raised its position in shares of The Cigna Group by 112.2% in the third quarter. VisionPoint Advisory Group LLC now owns 104 shares of the health services provider’s stock valued at $30,000 after buying an additional 55 shares in the last quarter. Finally, Pacifica Partners Inc. boosted its stake in shares of The Cigna Group by 73.2% in the fourth quarter. Pacifica Partners Inc. now owns 142 shares of the health services provider’s stock valued at $43,000 after buying an additional 60 shares during the period. Institutional investors and hedge funds own 86.99% of the company’s stock.

Insider Activity at The Cigna Group

In related news, CEO David Cordani sold 31,209 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $355.17, for a total transaction of $11,084,500.53. Following the completion of the sale, the chief executive officer now owns 348,054 shares of the company’s stock, valued at $123,618,339.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other The Cigna Group news, CEO David Cordani sold 31,209 shares of The Cigna Group stock in a transaction on Monday, March 25th. The shares were sold at an average price of $355.17, for a total value of $11,084,500.53. Following the completion of the sale, the chief executive officer now directly owns 348,054 shares of the company’s stock, valued at $123,618,339.18. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Hoeltzel Mary T. Agoglia sold 4,867 shares of the stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $330.48, for a total transaction of $1,608,446.16. Following the transaction, the senior vice president now directly owns 2,102 shares in the company, valued at approximately $694,668.96. The disclosure for this sale can be found here. Insiders have sold a total of 114,144 shares of company stock worth $39,296,330 over the last quarter. Company insiders own 0.70% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. StockNews.com raised The Cigna Group from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 14th. Deutsche Bank Aktiengesellschaft upgraded shares of The Cigna Group from a “hold” rating to a “buy” rating and increased their price target for the stock from $355.00 to $370.00 in a research report on Thursday, February 1st. Oppenheimer restated an “outperform” rating and set a $360.00 price objective on shares of The Cigna Group in a research report on Wednesday, January 17th. Barclays began coverage on The Cigna Group in a research note on Wednesday, March 6th. They issued an “overweight” rating and a $393.00 price target on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $384.00 price objective on shares of The Cigna Group in a research report on Wednesday, April 10th. Two research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, The Cigna Group currently has an average rating of “Buy” and a consensus target price of $362.14.

The Cigna Group Stock Down 0.1 %

Shares of NYSE:CI opened at $352.70 on Wednesday. The firm has a market cap of $103.12 billion, a P/E ratio of 20.28, a P/E/G ratio of 1.08 and a beta of 0.56. The Cigna Group has a 12-month low of $240.50 and a 12-month high of $365.71. The business has a fifty day simple moving average of $349.03 and a 200 day simple moving average of $316.84. The company has a quick ratio of 0.67, a current ratio of 0.67 and a debt-to-equity ratio of 0.61.

The Cigna Group (NYSE:CI) last issued its quarterly earnings data on Friday, February 2nd. The health services provider reported $6.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.54 by $0.25. The company had revenue of $51.15 billion during the quarter, compared to the consensus estimate of $48.91 billion. The Cigna Group had a return on equity of 13.59% and a net margin of 2.64%. The firm’s revenue was up 11.8% compared to the same quarter last year. During the same period last year, the company earned $4.96 earnings per share. Analysts predict that The Cigna Group will post 28.36 earnings per share for the current year.

The Cigna Group Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 21st. Investors of record on Wednesday, March 6th were paid a dividend of $1.40 per share. This represents a $5.60 dividend on an annualized basis and a yield of 1.59%. The ex-dividend date was Tuesday, March 5th. This is an increase from The Cigna Group’s previous quarterly dividend of $1.23. The Cigna Group’s dividend payout ratio (DPR) is currently 32.20%.

The Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.